HK1224202A1 - 作為 抑制劑的伯甲醯胺 - Google Patents
作為 抑制劑的伯甲醯胺Info
- Publication number
- HK1224202A1 HK1224202A1 HK16112545.7A HK16112545A HK1224202A1 HK 1224202 A1 HK1224202 A1 HK 1224202A1 HK 16112545 A HK16112545 A HK 16112545A HK 1224202 A1 HK1224202 A1 HK 1224202A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- bik
- btk inhibitors
- primary carboxamides
- carboxamides
- primary
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Indole Compounds (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361839729P | 2013-06-26 | 2013-06-26 | |
US201361897577P | 2013-10-30 | 2013-10-30 | |
PCT/US2014/044247 WO2014210255A1 (en) | 2013-06-26 | 2014-06-26 | Primary carboxamides as btk inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1224202A1 true HK1224202A1 (zh) | 2017-08-18 |
Family
ID=52116191
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK16112545.7A HK1224202A1 (zh) | 2013-06-26 | 2016-11-01 | 作為 抑制劑的伯甲醯胺 |
Country Status (29)
Country | Link |
---|---|
US (4) | US9567339B2 (zh) |
EP (3) | EP3483167A1 (zh) |
JP (3) | JP6509838B2 (zh) |
KR (1) | KR102273997B1 (zh) |
CN (1) | CN105530932B (zh) |
AU (3) | AU2014302365B2 (zh) |
BR (1) | BR112015032330B1 (zh) |
CA (1) | CA2916298C (zh) |
CY (1) | CY1121146T1 (zh) |
DK (1) | DK3013337T3 (zh) |
ES (1) | ES2708998T3 (zh) |
HK (1) | HK1224202A1 (zh) |
HR (1) | HRP20190093T1 (zh) |
HU (1) | HUE040645T2 (zh) |
IL (2) | IL243332B (zh) |
LT (1) | LT3013337T (zh) |
ME (1) | ME03307B (zh) |
MX (1) | MX355943B (zh) |
NZ (1) | NZ754039A (zh) |
PL (1) | PL3013337T3 (zh) |
PT (1) | PT3013337T (zh) |
RS (1) | RS58273B1 (zh) |
RU (1) | RU2708395C2 (zh) |
SG (2) | SG11201510503UA (zh) |
SI (1) | SI3013337T1 (zh) |
TW (1) | TWI642657B (zh) |
UY (1) | UY35630A (zh) |
WO (1) | WO2014210255A1 (zh) |
ZA (1) | ZA201509012B (zh) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2014302365B2 (en) * | 2013-06-26 | 2018-11-15 | Abbvie Inc. | Primary carboxamides as BTK inhibitors |
WO2015048662A2 (en) | 2013-09-30 | 2015-04-02 | X-Rx Discovery, Inc. | Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease |
TN2017000119A1 (en) * | 2014-10-24 | 2018-07-04 | Bristol Myers Squibb Co | Indole carboxamides compounds useful as kinase inhibitors |
AR104259A1 (es) * | 2015-04-15 | 2017-07-05 | Celgene Quanticel Res Inc | Inhibidores de bromodominio |
ES2764523T3 (es) * | 2015-07-27 | 2020-06-03 | Lilly Co Eli | Compuestos de 7-feniletilamino-4H-pirimido[4,5-D][1,3]oxazin-2-ona y su uso como inhibidores de IDH1 mutantes |
WO2017070089A1 (en) | 2015-10-19 | 2017-04-27 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US10716788B2 (en) * | 2015-11-17 | 2020-07-21 | Merck Patent Gmbh | Methods for treating MS using pyrimidine and pyridine compounds with BTK inhibitory activity |
HUE060680T2 (hu) | 2015-11-19 | 2023-04-28 | Incyte Corp | Heterociklusos vegyületek mint immunmodulátorok |
MY196319A (en) | 2015-12-17 | 2023-03-24 | Merck Patent Gmbh | Polycyclic TLR7/8 Antagonists and use Thereof in the Treatment of Immune Disorders |
CR20180374A (es) | 2015-12-22 | 2018-10-16 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
AR108396A1 (es) | 2016-05-06 | 2018-08-15 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
US20170335530A1 (en) * | 2016-05-23 | 2017-11-23 | Fatu K. Kofa | Pet waste vacuum and disposal device and method |
ES2905980T3 (es) | 2016-05-26 | 2022-04-12 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
CN105924840A (zh) * | 2016-06-01 | 2016-09-07 | 扬州兰都塑料科技有限公司 | 一种阻燃电力电缆 |
CN105837993A (zh) * | 2016-06-01 | 2016-08-10 | 扬州兰都塑料科技有限公司 | 一种阻燃电力电缆用阻燃剂 |
CN106083707B (zh) * | 2016-06-01 | 2018-10-26 | 温州大学 | 一种非对称杂芳基硫醚的合成方法 |
CN105884673B (zh) * | 2016-06-03 | 2018-05-11 | 温州大学 | 一种吲哚衍生物的合成方法 |
LT3472167T (lt) | 2016-06-20 | 2022-11-10 | Incyte Corporation | Heterocikliniai junginiai kaip imunomoduliatoriai |
US20180016260A1 (en) | 2016-07-14 | 2018-01-18 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
SG11201900947RA (en) | 2016-08-08 | 2019-02-27 | Merck Patent Gmbh | Tlr7/8 antagonists and uses thereof |
EP3504198B1 (en) | 2016-08-29 | 2023-01-25 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
RS61285B1 (sr) * | 2016-09-02 | 2021-02-26 | Bristol Myers Squibb Co | Proces pripreme jedinjenja indol karboksamida |
EP3527570A4 (en) | 2016-10-14 | 2020-04-15 | Jiangsu Hengrui Medicine Co., Ltd. | FIVE-LINKED HETERARYARYLE CYCLE BRIDGE DERIVATIVE, METHOD FOR PREPARING SAME, AND MEDICAL USE THEREOF |
CA3046961A1 (en) | 2016-12-12 | 2018-06-21 | Multivir Inc. | Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases |
EP3558985B1 (en) | 2016-12-22 | 2022-09-07 | Incyte Corporation | Benzooxazole derivatives as immunomodulators |
WO2018119236A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Triazolo[1,5-a]pyridine derivatives as immunomodulators |
CR20190317A (es) | 2016-12-22 | 2019-09-13 | Incyte Corp | Compuestos inmunomodulares y métodos de uso |
US20180179179A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
EP3573964A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Benzothiophene and benzothiazole compounds and methods of use thereof |
JP2020505395A (ja) * | 2017-01-26 | 2020-02-20 | アラクセス ファーマ エルエルシー | 縮合n−複素環式化合物およびその使用方法 |
CN106928201B (zh) * | 2017-02-22 | 2019-08-23 | 江汉大学 | 合成2-乙烯基吲哚衍生物的方法 |
WO2018218069A1 (en) | 2017-05-25 | 2018-11-29 | Araxes Pharma Llc | Quinazoline derivatives as modulators of mutant kras, hras or nras |
CN107098845A (zh) * | 2017-07-06 | 2017-08-29 | 贵州大学 | 一种5‑氰基‑6‑硝基吲哚的制备工艺 |
CN107721988A (zh) * | 2017-10-31 | 2018-02-23 | 无锡福祈制药有限公司 | 具有抗炎活性的异吲哚‑1‑酮类化合物 |
US11100492B2 (en) | 2018-02-19 | 2021-08-24 | Peter Garrett | General purpose re-loadable card aggregation implementation |
PT3774791T (pt) | 2018-03-30 | 2023-03-03 | Incyte Corp | Compostos heterocíclicos como imunomoduladores |
SI3790877T1 (sl) | 2018-05-11 | 2023-06-30 | Incyte Corporation | Tetrahidro-imidazo(4,5-c)piridinski derivati kot imunomodulatorji pd-l1 |
CN114364798A (zh) | 2019-03-21 | 2022-04-15 | 欧恩科斯欧公司 | 用于治疗癌症的Dbait分子与激酶抑制剂的组合 |
CA3150434A1 (en) | 2019-08-09 | 2021-02-18 | Incyte Corporation | Salts of a pd-1/pd-l1 inhibitor |
PE20221038A1 (es) | 2019-09-30 | 2022-06-17 | Incyte Corp | Compuestos de pirido[3,2-d] pirimidina como inmunomoduladores |
AU2020378630A1 (en) | 2019-11-08 | 2022-05-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
AU2020385113A1 (en) | 2019-11-11 | 2022-05-19 | Incyte Corporation | Salts and crystalline forms of a PD-1/PD-L1 inhibitor |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
US11807644B2 (en) | 2020-05-12 | 2023-11-07 | Pmv Pharmaceuticals, Inc. | Methods and compounds for restoring mutant p53 function |
EP4157446A1 (en) * | 2020-06-02 | 2023-04-05 | GB002, Inc. | Kinase inhibitors |
BR112022025692A2 (pt) | 2020-06-19 | 2023-02-28 | Bayer Ag | 1,3,4-oxadiazóis e seus derivados como fungicidas |
TW202206103A (zh) | 2020-08-04 | 2022-02-16 | 瑞士商諾華公司 | Cll的治療 |
JP2023543299A (ja) | 2020-09-30 | 2023-10-13 | アストラゼネカ・アクチエボラーグ | 化合物及び癌の治療におけるそれらの使用 |
US20230382900A1 (en) * | 2020-10-30 | 2023-11-30 | Newave Pharmaceutical Inc. | Inhibitors of btk |
US11780836B2 (en) | 2020-11-06 | 2023-10-10 | Incyte Corporation | Process of preparing a PD-1/PD-L1 inhibitor |
WO2022099075A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Crystalline form of a pd-1/pd-l1 inhibitor |
EP4240739A1 (en) | 2020-11-06 | 2023-09-13 | Incyte Corporation | Process for making a pd-1/pd-l1 inhibitor and salts and crystalline forms thereof |
KR20230131251A (ko) * | 2021-01-12 | 2023-09-12 | 쥐비005 인코포레이티드 | 키나아제 억제제로서의 인돌 유도체 |
CN114957241B (zh) * | 2021-02-23 | 2023-08-22 | 药雅科技(上海)有限公司 | 杂环类化合物作为激酶抑制剂的制备及其应用 |
US20240190864A1 (en) * | 2021-02-03 | 2024-06-13 | Ya Therapeutics Inc | Bruton's Tyrosine Kinase (BTK) INHIBITOR AND APPLICATION THEREOF |
CN114853723B (zh) * | 2021-02-03 | 2023-11-24 | 药雅科技(上海)有限公司 | 吲哚类化合物btk抑制剂的制备及其应用 |
CN114957242B (zh) * | 2021-02-23 | 2023-08-22 | 药雅科技(上海)有限公司 | 吡啶并杂环类化合物作为激酶抑制剂的制备及其应用 |
CN114853752B (zh) * | 2021-02-03 | 2023-08-22 | 药雅科技(上海)有限公司 | Btk抑制剂吡啶并杂环类化合物的制备及其应用 |
WO2022228302A1 (en) * | 2021-04-25 | 2022-11-03 | Bionova Pharmaceuticals (Shanghai) Limited | Heteroaromatic carboxamide compounds and its use |
CN115521313B (zh) * | 2021-06-24 | 2023-11-03 | 山东大学 | 一种降解btk蛋白的化合物及其制备方法和应用 |
WO2023147419A2 (en) | 2022-01-27 | 2023-08-03 | Pmv Pharmaceuticals, Inc. | Deuterated compounds for restoring mutant p53 function |
WO2023227080A1 (zh) * | 2022-05-25 | 2023-11-30 | 百极弘烨(南通)医药科技有限公司 | 一种protac化合物、含其的药物组合物及其制备方法和应用 |
WO2023250431A2 (en) * | 2022-06-22 | 2023-12-28 | Children's Hospital Medical Center | Multi-cyclic irak and flt3 inhibiting compounds and uses thereof |
WO2024081748A2 (en) * | 2022-10-12 | 2024-04-18 | Maze Therapeutics, Inc. | Inhibitors of solute carrier family 6a member 19 (slc6a19) and methods of use thereof |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4025510A (en) * | 1975-12-01 | 1977-05-24 | E. I. Du Pont De Nemours And Company | 2,4-Diaryl[1,3,4H]thiadiazines fused to quinoxalines |
US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
DE10022925A1 (de) * | 2000-05-11 | 2001-11-15 | Basf Ag | Substituierte Indole als PARP-Inhibitoren |
WO2003009852A1 (en) * | 2001-07-24 | 2003-02-06 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
WO2004041285A1 (en) * | 2002-10-31 | 2004-05-21 | Amgen Inc. | Antiinflammation agents |
US7329764B2 (en) | 2003-07-31 | 2008-02-12 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substitute benzothiophene compounds |
GB0400895D0 (en) * | 2004-01-15 | 2004-02-18 | Smithkline Beecham Corp | Chemical compounds |
KR100796965B1 (ko) * | 2004-05-04 | 2008-01-22 | 에프. 호프만-라 로슈 아게 | Ikk 저해제로서의 티에노피리딘 |
WO2005121140A1 (en) | 2004-06-09 | 2005-12-22 | Glaxo Group Limited | Pyrrolopyridine derivatives |
PE20060748A1 (es) * | 2004-09-21 | 2006-10-01 | Smithkline Beecham Corp | Derivados de indolcarboxamida como inhibidores de quinasa ikk2 |
BRPI0608659A2 (pt) * | 2005-04-06 | 2010-11-30 | Astrazeneca Ab | composto, métodos para limitar a proliferação celular, de tratamento de um ser humano ou animal sofrendo de uma doença, e de tratamento de profilaxia do cáncer, para tratar cáncer, de tratamento de infecções associadas com cáncer, e de profilaxia de infecções associadas com cáncer, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, métodos para inibir chk1 cinase, e um pak cinase, e para limitar a tumorigênese em um ser humano ou animal, e, processo para a preparação de um composto ou um sal farmaceuticamente aceitável do mesmo |
CN101189243A (zh) * | 2005-04-06 | 2008-05-28 | 阿斯利康(瑞典)有限公司 | 取代的杂环及其作为chk1、pdk1和pak抑制剂的应用 |
PE20070173A1 (es) * | 2005-06-30 | 2007-03-14 | Smithkline Beecham Corp | Compuestos de indol carboxamidas como inhibidores de ikk2 |
US8063071B2 (en) * | 2007-10-31 | 2011-11-22 | GlaxoSmithKline, LLC | Chemical compounds |
AU2007232297B2 (en) | 2006-04-03 | 2012-09-20 | Msd Italia S.R.L. | Amide substituted indazole and benzotriazole derivatives as poly(ADP-ribose)polymerase (PARP) inhibitors |
PE20081889A1 (es) * | 2007-03-23 | 2009-03-05 | Smithkline Beecham Corp | Indol carboxamidas como inhibidores de ikk2 |
CA2684240A1 (en) * | 2007-04-16 | 2008-10-30 | Serenex, Inc. | Tetrahydroindole and tetrahydroindazole derivatives |
US20100226917A1 (en) * | 2007-04-27 | 2010-09-09 | Astrazeneca Ab | Methods for the treatment of hematologic malignancies |
EP2152318A4 (en) | 2007-06-01 | 2011-12-07 | Abbott Biotech Ltd | COMPOSITIONS AND USES FOR THE TREATMENT OF PSORIASIS AND CROHN'S DISEASE |
CN101481380B (zh) * | 2008-01-08 | 2012-10-17 | 浙江医药股份有限公司新昌制药厂 | 噻吩并哒嗪类化合物及其制备方法、药物组合物及其用途 |
AR070317A1 (es) | 2008-02-06 | 2010-03-31 | Osi Pharm Inc | Furo (3,2-c) piridina y tieno (3,2-c) piridinas |
US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
US8084620B2 (en) * | 2008-12-19 | 2011-12-27 | Bristol-Myers Squibb Company | Carbazole carboxamide compounds useful as kinase inhibitors |
EP2473049B1 (en) | 2009-09-04 | 2018-11-28 | Biogen MA Inc. | Bruton's tyrosine kinase inhibitors |
US8772301B2 (en) | 2009-12-18 | 2014-07-08 | Sunovion Pharmaceuticals, Inc. | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
US20110212461A1 (en) | 2010-02-26 | 2011-09-01 | Hans Marcus Ludwig Bitter | Prediction of cardiotoxicity |
CN103003281A (zh) | 2010-05-20 | 2013-03-27 | 弗·哈夫曼-拉罗切有限公司 | 作为JAK和SYK抑制剂的吡咯并[2,3-b]吡嗪-7-甲酰胺衍生物和它们的用途 |
EP2582668B1 (en) | 2010-06-16 | 2016-01-13 | Bristol-Myers Squibb Company | Carboline carboxamide compounds useful as kinase inhibitors |
EP2592933B1 (en) | 2010-07-16 | 2017-04-05 | Anderson Gaweco | Mif inhibitors and their uses |
EP2616072A1 (en) | 2010-09-15 | 2013-07-24 | F.Hoffmann-La Roche Ag | Azabenzothiazole compounds, compositions and methods of use |
FR2969151B1 (fr) * | 2010-12-17 | 2016-11-04 | Oreal | Derives du 4-amino et leur utilisation pour la coloration d'oxydation des fibres keratiniques. |
EP2696682B1 (en) | 2011-04-13 | 2018-03-21 | Innovimmune Biotherapeutics, Inc. | Mif inhibitors and their uses |
EP2561759A1 (en) * | 2011-08-26 | 2013-02-27 | Bayer Cropscience AG | Fluoroalkyl-substituted 2-amidobenzimidazoles and their effect on plant growth |
WO2013148603A1 (en) | 2012-03-27 | 2013-10-03 | Takeda Pharmaceutical Company Limited | Cinnoline derivatives as as btk inhibitors |
AU2014302365B2 (en) * | 2013-06-26 | 2018-11-15 | Abbvie Inc. | Primary carboxamides as BTK inhibitors |
-
2014
- 2014-06-26 AU AU2014302365A patent/AU2014302365B2/en active Active
- 2014-06-26 SG SG11201510503UA patent/SG11201510503UA/en unknown
- 2014-06-26 EP EP18202730.0A patent/EP3483167A1/en not_active Withdrawn
- 2014-06-26 EP EP21194489.7A patent/EP4008328A1/en active Pending
- 2014-06-26 PL PL14817453T patent/PL3013337T3/pl unknown
- 2014-06-26 UY UY0001035630A patent/UY35630A/es active IP Right Grant
- 2014-06-26 TW TW103122168A patent/TWI642657B/zh active
- 2014-06-26 HU HUE14817453A patent/HUE040645T2/hu unknown
- 2014-06-26 BR BR112015032330-8A patent/BR112015032330B1/pt active IP Right Grant
- 2014-06-26 DK DK14817453.5T patent/DK3013337T3/en active
- 2014-06-26 RU RU2016102137A patent/RU2708395C2/ru active
- 2014-06-26 LT LTEP14817453.5T patent/LT3013337T/lt unknown
- 2014-06-26 ME MEP-2019-21A patent/ME03307B/me unknown
- 2014-06-26 KR KR1020167002152A patent/KR102273997B1/ko active IP Right Grant
- 2014-06-26 PT PT14817453T patent/PT3013337T/pt unknown
- 2014-06-26 US US14/315,504 patent/US9567339B2/en active Active
- 2014-06-26 SI SI201431050T patent/SI3013337T1/sl unknown
- 2014-06-26 CN CN201480047196.8A patent/CN105530932B/zh active Active
- 2014-06-26 CA CA2916298A patent/CA2916298C/en active Active
- 2014-06-26 NZ NZ754039A patent/NZ754039A/en unknown
- 2014-06-26 WO PCT/US2014/044247 patent/WO2014210255A1/en active Application Filing
- 2014-06-26 ES ES14817453T patent/ES2708998T3/es active Active
- 2014-06-26 EP EP14817453.5A patent/EP3013337B1/en active Active
- 2014-06-26 RS RS20190083A patent/RS58273B1/sr unknown
- 2014-06-26 SG SG10201802444XA patent/SG10201802444XA/en unknown
- 2014-06-26 MX MX2015017973A patent/MX355943B/es active IP Right Grant
- 2014-06-26 JP JP2016524175A patent/JP6509838B2/ja active Active
-
2015
- 2015-12-10 ZA ZA2015/09012A patent/ZA201509012B/en unknown
- 2015-12-24 IL IL243332A patent/IL243332B/en active IP Right Grant
-
2016
- 2016-11-01 HK HK16112545.7A patent/HK1224202A1/zh unknown
-
2017
- 2017-01-05 US US15/398,978 patent/US20170174624A1/en not_active Abandoned
-
2019
- 2019-01-16 HR HRP20190093TT patent/HRP20190093T1/hr unknown
- 2019-01-18 CY CY20191100073T patent/CY1121146T1/el unknown
- 2019-02-08 AU AU2019200901A patent/AU2019200901A1/en not_active Abandoned
- 2019-04-02 JP JP2019070362A patent/JP6770127B2/ja active Active
- 2019-05-23 US US16/421,006 patent/US20190284135A1/en not_active Abandoned
- 2019-06-05 IL IL267101A patent/IL267101A/en unknown
-
2020
- 2020-09-24 JP JP2020159339A patent/JP2021001212A/ja active Pending
-
2021
- 2021-02-11 US US17/173,613 patent/US20210179556A1/en not_active Abandoned
- 2021-03-08 AU AU2021201463A patent/AU2021201463A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL267101A (en) | Primary carboxamides as btk inhibitors | |
EP2948458A4 (en) | BTK INHIBITORS | |
HRP20182063T1 (hr) | Gen otpornosti na rizomaniju | |
EP2948431A4 (en) | BTK INHIBITORS | |
EP3008633A4 (en) | QUICK GROUPING OF TIME SERIES | |
EP2968282A4 (en) | HISTONDEMENTHYLASEINHIBITOREN | |
EP3082809A4 (en) | Btk inhibitors | |
HK1216531A1 (zh) | 新的抑制劑 | |
EP3082811A4 (en) | Btk inhibitors | |
SI2943561T1 (sl) | Fotobioreaktor | |
EP3632467C0 (en) | INHIBITORS OF COMPLEMENT FACTOR H | |
HK1222339A1 (zh) | 金屬-β-內酰胺酶的抑制劑 | |
GB201301346D0 (en) | Well completion | |
GB201322992D0 (en) | New Process | |
GB201317756D0 (en) | New process | |
GB201313211D0 (en) | New process | |
GB201305503D0 (en) | Inhibitor | |
GB201303355D0 (en) | Zippy Doodah |